Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

POEM-F for Achalasia International Study

NCT06042127 · View on ClinicalTrials.gov ↗

Study Summary

Per-oral endoscopic myotomy (POEM) has emerged as the endoscopic treatment of choice for achalasia, offering comparable symptom relief with laparoscopic Heller's cardiomyotomy. The main concern with POEM is the higher incidence of post-procedure gastroesophageal reflux disease (GERD), occurring in up to 50-60% of patients. In order to reduce the risk of GERD, endoscopic fundoplication has been developed as a novel procedure mimicking surgical anterior partial fundoplication that can be performed in the same session as POEM (POEM-F). Case series of POEM-F in patients with achalasia reported encouraging outcomes of low GERD rate of \~12% at 1 year. Prospective comparative data between POEM-F and conventional POEM on post-procedure GERD is current lacking. The investigators therefore designed an international multicenter prospective randomized study to investigate the efficacy of POEM-F. The investigators postulate that POEM-F could reduce the incidence of post-procedure GERD when compared with conventional POEM. This is an international multicenter randomized controlled trial conducted between high volume expert centers from Hong Kong SAR, China, India and United States of America. Adult patients with manometry confirmed achalasia would be randomised to undergo POEM-F or POEM. The procedure would be performed by experts with vast experience in POEM. The primary outcome is the incidence of post-procedure GERD at 1 year, defined by the updated Lyon consensus. Secondary outcomes include technical and clinical success rates, adverse events, post-POEM endoscopic and manometry findings as well as patients' symptom scores. Sample size calculation Based on existing pilot comparative data on POEM-F and POEM, it is estimated that 84 patients would be required to demonstrate a difference in post-procedure GERD of 47.6% to 18.2%, with 80% power and false positive rate of 0.05, accounting for 10% loss to follow-up. Purpose and potential The current study proposal could demonstr

Conditions Studied

Interventions

  • PROCEDURE POEM-F
  • PROCEDURE Conventional POEM

Study Locations (7)

Other

  • Nanfang Hospital, Southern Medical University — Guangzhou
  • The Chinese University of Hong Kong — Hong Kong
  • Post Graduate Institute of Medical Education and Research — Chandigarh
  • Asian Institute of Gastroenterology — Hyderabad
  • Baldota Institute of Digestive Sciences — Mumbai
  • Deenanath Mangeshkar Hospital & Research Center — Pune

Maryland

  • Johns Hopkins Hospital — Baltimore

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2023-12-01
Est. Completion 2026-10-31
Phase NA

Sponsor

Chinese University of Hong Kong

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06042127

The ClinicalTrials.gov registry entry for NCT06042127 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chinese University of Hong Kong, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Achalasia appearing as the primary indexed condition, and to 2 interventions — of which POEM-F is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06042127 reports 7 study locations spanning 2 distinct geographic areas — top geographies include Other, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06042127 about?

NCT06042127 is a clinical study titled "POEM-F for Achalasia International Study". Per-oral endoscopic myotomy (POEM) has emerged as the endoscopic treatment of choice for achalasia, offering comparable symptom relief with laparoscopic Heller's cardiomyotomy. The main concern with POEM is the higher incidence of post-procedure gastroesophageal reflux disease (GERD), occurring in u...

What is the current status of trial NCT06042127?

This trial is currently recruiting. It is a NA study. The enrollment target is 81 participants. The study started on 2023-12-01. Estimated completion is 2026-10-31.

What conditions does trial NCT06042127 study?

This clinical trial studies the following conditions: Achalasia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06042127?

The interventions under investigation include: POEM-F (PROCEDURE), Conventional POEM (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06042127?

This trial is sponsored by Chinese University of Hong Kong, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06042127 being conducted?

This trial has 7 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial